In-vitro and in-vivo evaluation of austocystin D liposomes

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 3, 2013, Pages 355-362

  Li, Shuo ^a   Hu, Jie ^b   Zhang, Li ^c   Zhang, Linan ^a   Sun, Yongjun ^a   Xie, Yinghua ^a   Wu, Shaomei ^a   Liu, Lei ^a   Gao, Zibin ^a  

^a HEBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c North China Pharmaceutical Corporation   (China)

Author keywords

anti tumour; austocystin D; liposomes; passive targeting; pharmacokinetics

Indexed keywords

AUSTOCYSTIN D; CYTOTOXIC AGENT; LIPOSOME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN HT29; CHEMICAL STRUCTURE; COLORECTAL CANCER; CONTROLLED STUDY; DISPERSION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SCREENING; DRUG TARGETING; DRUG TISSUE LEVEL; ENCAPSULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MEAN RETENTION TIME; MOUSE; NONHUMAN; PARTICLE SIZE; PHARMACOLOGICAL PARAMETERS; STRUCTURE ANALYSIS; SUSPENSION; TRANSMISSION ELECTRON MICROSCOPY; ULTRASOUND; ZETA POTENTIAL;

AFLATOXINS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG CARRIERS; DRUG SCREENING ASSAYS, ANTITUMOR; HT29 CELLS; HUMANS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; PARTICLE SIZE; RANDOM ALLOCATION; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873083949     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01606.x     Document Type: Article

References (28)

1. Steyn PS, Austocystins VR,. Six novel dihydrofuro (3′,2′: 4,5) furo (3,2-b) xanthenones from Aspergillus ustus. J Chem Soc Perkin 1974; 1: 2250-2256.
2. Ireland CM, et al. Anticancer agents from unique natural products sources. Pharm Biol 2003; 41: 15-38.
3. Marks KM, et al. The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes. J Nat Prod 2011; 74: 567-573.
4. Kfir R, et al. Mutagenic activity of austocystins-secondary metabolites of Aspergillus ustus. Bull Environ Contam Toxicol 1986; 37: 643-650.
5. Shekhar C,. Lean and mean: nanoparticle-based delivery improves performance of cancer drugs. Chem Biol 2009; 16: 349-350.
6. Maruyama K,. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev 2011; 63: 161-169.
7. Yang F, et al. Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside. Cancer Treat Rev 2011; 37: 633-642.
8. Torchilin VP,. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4: 145-160.
9. Ogawara K, et al. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: involvement of cytotoxic effect on vascular endothelial cells. J Control Release 2009; 133: 4-10.
10. Yang T, et al. Liposome formulation of paclitaxel with enhanced solubility and stability. Drug Deliv 2007; 14: 301-308.
11. Li R, et al. All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. J Control Release 2011; 149: 281-291.
12. Du B, et al. Preparation, characterization and in vivo evaluation of 2-methoxyestradiol-loaded liposomes. Int J Pharm 2010; 384: 140-147.
13. El-Samaligy MS, et al. Increasing bioavailability of silymarin using a buccal liposomal delivery system: preparation and experimental design investigation. Int J Pharm 2006; 308: 140-148.
14. Zhang JA, et al. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm 2005; 59: 177-187.
15. Guan P, et al. Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. Int J Nanomedicine 2011; 6: 965-974.
16. Drummond DC, et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999; 51: 691-743.
17. Liu D, et al. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim Biophys Acta 1992; 1104: 95-101.
18. Rathore SS, Ghosh PC,. Effect of surface charge and density of distearylphosphatidylethanolamine-mPEG-2000 (DSPE-mPEG-2000) on the cytotoxicity of liposome-entrapped ricin: effect of lysosomotropic agents. Int J Pharm 2008; 350: 79-94.
19. Sun W, et al. Preparation and evaluation of N (3)-O-toluyl-fluorouracil- loaded liposomes. Int J Pharm 2008; 353: 243-250.
20. Takakura Y, et al. Influence of physicochemical properties on pharmacokinetics of non-viral vectors for gene delivery. J Drug Target 2002; 10: 99-104.
21. Mobed M, Chang TM,. Comparison of polymerically stabilized PEG-grafted liposomes and physically adsorbed carboxymethylchitin and carboxymethyl/ glycolchitin liposomes for biological applications. Biomaterials 1998; 19: 1167-1177.
22. Gabizon A, Papahadjopoulos D,. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta 1992; 1103: 94-100.
23. Glavas-Dodov M, et al. The effects of lyophilization on the stability of liposomes containing 5-FU. Int J Pharm 2005; 291: 79-86.
24. Cocera M, et al. Alterations in stratum corneum lipid liposomes due to the action of triton X-100. Influence of the level of ceramides on this process. J Control Release 2000; 68: 387-396.
25. Laouini A, et al. Liposome preparation using a hollow fiber membrane contactor-application to spironolactone encapsulation. Int J Pharm 2011; 415: 53-61.
26. Palakurthi S, et al. Biodisposition of PEG-coated lipid microspheres of indomethacin in arthritic rats. Int J Pharm 2005; 290: 55-62.
27. Ogawara K, et al. Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors. Int J Pharm 2008; 359: 234-240.
28. Fung VW, et al. Application of purging biotinylated liposomes from plasma to elucidate influx and efflux processes associated with accumulation of liposomes in solid tumors. Biochim Biophys Acta 2003; 1611: 63-69.